These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9325637)

  • 21. Organ manifestations influence differently the responsiveness of 2 lupus disease activity measures, according to patients' or physicians' evaluations of recent lupus activity.
    Chang ER; Abrahamowicz M; Ferland D; Fortin PR
    J Rheumatol; 2002 Nov; 29(11):2350-8. PubMed ID: 12415591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Poor prognosis factors in SLE: results of 5-year follow-up].
    Sushchuk EA; Zborovskiĭ AB
    Ter Arkh; 2009; 81(6):16-9. PubMed ID: 19663186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initial and accrued damage as predictors of mortality in Brazilian patients with systemic lupus erythematosus: a cohort study.
    Cardoso CR; Signorelli FV; Papi JA; Salles GF
    Lupus; 2008 Nov; 17(11):1042-8. PubMed ID: 18852231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinically active serologically quiescent systemic lupus erythematosus.
    Gladman DD; Hirani N; Ibañez D; Urowitz MB
    J Rheumatol; 2003 Sep; 30(9):1960-2. PubMed ID: 12966598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lupus: improving long-term prognosis.
    Doria A; Briani C
    Lupus; 2008 Mar; 17(3):166-70. PubMed ID: 18372355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic lupus erythematosus and lupus syndromes in Senegal. A retrospective study of 30 patients seen over 10 years.
    Ka MM; Diallo S; Kane A; Wade B; Diouf B; Diallo A; Moreira-Diop T
    Rev Rhum Engl Ed; 1998; 65(7-9):471-6. PubMed ID: 9785393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome measures to be used in clinical trials in systemic lupus erythematosus.
    Strand V; Gladman D; Isenberg D; Petri M; Smolen J; Tugwell P
    J Rheumatol; 1999 Feb; 26(2):490-7. PubMed ID: 9972993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity.
    American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria
    Arthritis Rheum; 2004 Nov; 50(11):3418-26. PubMed ID: 15529383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic lupus erythematosus in a multiethnic US cohort. XXXIII. Clinical [corrected] features, course, and outcome in patients with late-onset disease.
    Bertoli AM; Alarcón GS; Calvo-Alén J; Fernández M; Vilá LM; Reveille JD;
    Arthritis Rheum; 2006 May; 54(5):1580-7. PubMed ID: 16645994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accrual of organ damage over time in patients with systemic lupus erythematosus.
    Gladman DD; Urowitz MB; Rahman P; Ibañez D; Tam LS
    J Rheumatol; 2003 Sep; 30(9):1955-9. PubMed ID: 12966597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus.
    Nived O; Jönsen A; Bengtsson AA; Bengtsson C; Sturfelt G
    J Rheumatol; 2002 Jul; 29(7):1398-400. PubMed ID: 12136895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus.
    Uribe AG; Vilá LM; McGwin G; Sanchez ML; Reveille JD; Alarcón GS
    J Rheumatol; 2004 Oct; 31(10):1934-40. PubMed ID: 15468356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severe clinical course of systemic lupus erythematosus in the first year of life.
    Zulian F; Pluchinotta F; Martini G; Da Dalt L; Zacchello G
    Lupus; 2008 Sep; 17(9):780-6. PubMed ID: 18755858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women.
    Fernández M; Calvo-Alén J; Alarcón GS; Roseman JM; Bastian HM; Fessler BJ; McGwin G; Vilá LM; Sanchez ML; Reveille JD
    Arthritis Rheum; 2005 Jun; 52(6):1655-64. PubMed ID: 15934092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Socioeconomic factors in lupus erythematosus.
    Meller S; Homey B; Ruzicka T
    Autoimmun Rev; 2005 Apr; 4(4):242-6. PubMed ID: 15893719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of menopause on disease activity in systemic lupus erythematosus.
    Urowitz MB; Ibañez D; Jerome D; Gladman DD
    J Rheumatol; 2006 Nov; 33(11):2192-8. PubMed ID: 16981295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies.
    Descloux E; Durieu I; Cochat P; Vital Durand D; Ninet J; Fabien N; Cimaz R
    Rheumatology (Oxford); 2008 Feb; 47(2):183-7. PubMed ID: 18160418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hyperprolactinemia in systemic lupus erythematosus. A prospective study of 38 cases].
    Smiti Khanfir M; Ben Ghorbel I; Feki M; Lamloum M; Mebazaa A; Miled M; Houman MH
    Tunis Med; 2004 Jun; 82(6):512-5. PubMed ID: 15517949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pregnancy and systemic lupus erythematosus].
    Wechsler B; Lê Thi Huong D; Piette JC
    Ann Med Interne (Paris); 1999 Sep; 150(5):408-18. PubMed ID: 10544751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus.
    Brunner HI; Gladman DD; Ibañez D; Urowitz MD; Silverman ED
    Arthritis Rheum; 2008 Feb; 58(2):556-62. PubMed ID: 18240232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.